Abstract:Metabolic dysfunction-associated steatotic liver disease（MASLD）is a prevalent liver condition among elderly individuals，which is closely linked to cardiovascular and renal diseases，metabolic abnormalities，and a range of hepatic complications. Given the global trend towards an aging population，the prevalence of MASLD in elderly cohorts has markedly increased. Although the direct impact of MASLD on all-cause mortality is relatively limited，its negative effects on specific disease-related mortality and patient quality of life cannot be disregarded. The therapeutic measures for elderly patients with MASLD encompass active lifestyle modifications，pharmacotherapy，and necessary surgical procedures. Early-stage screening and individualized precise treatment plans are of vital importance for enhancing the prognosis of patients. Future relevant research will aim to refine diagnostic and therapeutic protocols for MASLD in elderly populations，with a focus on developing novel pharmacotherapies，and endeavoring to bring more benefits to patients.